Virus Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Virus Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bird Flu
Canopus BioPharma's StatC Drug Shows Superior Results for Treatment of Avian Flu and Other Influenzas
August 14th, 2007
Canopus BioPharma, Inc. (OTC: CBIA), a biotechnology company developing pharmaceutical products and assay methods for patients suffering from infectious disease, bio-terrorism, cancer, and addiction, announced groundbreaking results in animal trials for its drug candidate StatC against Avian Flu, Spanish Flu and Hong Kong Flu strains. Studies performed using StatC have shown results which are superior to TAMIFLU, the leading influenza antiviral (estimated market size in excess of $2.2 billion) drug distributed in the United States by Roche Pharmaceuticals. Specifically, the research found that Canopus BioPharma's StatC is superior to TAMIFLU in preventing influenza in three different...
Source: Virus Weekly (2007-08-14)
|
